推荐产品
形狀
liquid
品質等級
比活性
Antibacterial
濃度
25 mg/mL in water
抗生素活性譜
Gram-negative bacteria
Gram-positive bacteria
mycobacteria
作用方式
protein synthesis | interferes
儲存溫度
2-8°C
SMILES 字串
O=C([C@@H](O)CCN)N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O3)[C@@H](N)C1.O=S(O)(O)=O.[F,Cl,Br,I]
InChI
1S/C22H43N5O13.H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1
InChI 密鑰
HIBICIOPDUTNRR-XTHCGPPUSA-N
一般說明
Amikacin is semisynthetic aminoglycoside antibiotic derived from kanamycin A. Amikacin has broad spectrum activity against serious gram-negative bacilli drug resistant infections and also mycobacteria type infections. Amikacin binds to 30S bacterial ribosomal subunit causing a change of conformation, thus disrupting mRNA’s interaction with tRNA and hampering bacterial growth. Amikacin also showed potency against some gram-positive bacteria like methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is extensively used for multidrug resistant tuberculosis treatment with 1ug/mL MIC value against Mycobacterium tuberculosis. Additionally, Amikacin MIC studies of gram negative and gram positive bacteria showed MIC distribution range of 0.094-48µg/ml. Several other studies showed that Amikacin has a synergistic effect combined with β-lactams against methicillin-resistant Staphylococcus spp. strains and Pseudomonas aeruginosa. Amikacin is additionally used for wound healing assays at concentration of 250 µg/mL.
其他說明
The suggested concentration of Amikacin for assays is 0.094-250 µg/mL therefore, it is recommended to dilute the ready made solution 1:100-266,000. Amikacin:Sulfate ratio 1:1.8
訊號詞
Warning
危險聲明
危險分類
Skin Sens. 1
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Toxics, 8(4) (2020-11-26)
(1) Background: Amikacin is an aminoglycoside antibiotic used for treating gram-negative bacterial infections in cancer patients. In this study, our aims are to investigate the migratory inhibition effects of amikacin in human MDA-MB-231 cells. (2) Methods: We used a wound-healing
Investigative ophthalmology & visual science, 51(5), 2519-2524 (2009-12-19)
To determine the minimum inhibitory concentrations (MICs) of 12 antimicrobials in current ophthalmic use and 4 potentially new alternatives against isolates from bacterial keratitis. Bacteria were collected from cases of bacterial keratitis in six centers in the United Kingdom between
In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains
Annals of Clinical Microbiology and Antimicrobials, 5, 1-5 (2006)
Drugs in R&D, 17(1), 177-187 (2017-01-08)
Amikacin has been one of the important antimicrobial agents against Gram-negative pathogens. However, there is discrepancy regarding the amikacin initial dosage, with some reports recently recommending ≥25 mg/kg and others the conventional dosage (15-20 mg/kg). Hence, we evaluated the optimal initial dosing
BB-K8, a new semisynthetic aminoglycoside antibiotic.
The Journal of Antibiotics, 12, 695-708 (1972)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门